Trial · NCT06947941
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
NCT06947941, Phase 3, Recruiting, Bristol-Myers Squibb
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5). Trials, record NCT06947941. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06947941
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
- NCT number
- NCT06947941
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 325 participants, estimated
- Lead sponsor
- Bristol-Myers Squibb
- Conditions
- Alzheimer Disease, Psychosis
- Interventions
- KarXT, KarX-EC, KarXT + KarX-EC Arm Matching Placebo
- First posted
- 2025-04-27
- Last updated
- 2026-06-30
Source ClinicalTrials.gov
Registered outcomes32
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions (NPI-C: H+D) Score | Up to approximately Week 14 | |
| Secondary | Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Score | Up to approximately Week 14 | |
| Secondary | Change From Baseline in Neuropsychiatric Inventory-Clinician Rating Scale (NPI-C) Core Score | Up to approximately Week 14 | NPI-C Core Score includes assessment for hallucinations, delusions, agitation, and aggression domains |
| Secondary | Change From Baseline in NPI-C: Agitation Score | Up to approximately Week 14 | |
| Secondary | Change From Baseline in NPI-C Core Score: Caregiver Distress Scale | Up to approximately Week 14 | NPI-C Core Score: Caregiver Distress Scale includes assessment for hallucinations, delusions, agitation, and aggression domains |
| Secondary | Responder Rate | Up to approximately Week 14 | Responder rate is defined as improvement from baseline in NPI-C: H+D score ≥ 40%. |
| Secondary | Change From Baseline in Cohen-Mansfield Agitation Inventory International Psychogeriatric Association (CMAI-IPA) Score | Up to approximately Week 14 | |
| Secondary | Change From Baseline in CMAI Total Score | Up to approximately Week 14 | |
| Secondary | Number of Participants With Adverse Events (AEs) | Up to approximately Week 14 | |
| Secondary | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Up to approximately Week 14 |
1 to 10 of 32Source ClinicalTrials.gov
See all 32 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06947941
GET https://conductscience.org/api/trials/v1/NCT06947941/registered?page=2